Stockopedia comments Paul Scott - HVO30 Jan 2024 09:17
HVIVO (LON:HVO)
Up 6% to 27.75p (£189m) - Trading Update - Paul
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces an unaudited trading update for the year ended 31 December 2023.
Revenue up 16% to £56m (slightly ahead of Cavendish previous forecast £55m)
EBITDA margins of c.22% (2022: 18.7%)
Cavendish now forecasts £12.8m adj EBITDA (previously £11.5m), an 11% upgrade today.
This becomes forecast adj PBT of £10.5m (previously £9.2m), a 14% upgrade today.
Adj EPS is increased from 1.3p to 1.5p, a PER of 18.5x - looks very reasonable to me, given the strong growth trajectory.
Outlook - HVO guides £62m revenue for 2024, 11% increase. That looks a fairly soft target, so hopefully can be beaten.
Excellent visibility -
“90% of 2024 revenue guidance already contracted and good visibility into 2025”
“Weighted contracted orderbook of £80 million as at 31 December 2023 (31 December 2022: £76 million)”
“New medium-term target of growing Group revenue to £100m by 2028”
R&D tax credits look a useful contributor to profit -
…the Group also recognised Other Income relating to R&D tax credits of £2.6 million (2022: £2.2 million).
Cash - it gets paid a lot up-front, which is an attractive feature of this share (demonstrating pricing power, and client commitment) -
hVIVO is a highly cash generative business with cash of £37.0 million as at 31 December 2023 (31 December 2022: £28.4 million). This increase in cash generation is due to improved margins and the upfront non-refundable quarantine booking fee from new contracts.
Dividends - it says annual divis will commence, more details to follow.
New premises are coming on stream soon, which should help further growth -
The new facility will substantially boost our revenue potential and should lead to improved operational efficiencies and enhanced margins.
Paul’s opinion - this all reads very well I think. Despite a strong recent surge in share price, I think today’s forecast upgrade (FY 12/2023) and positive outlook makes the valuation still reasonable, and the visibility for 2024 looks excellent, with more earnings beats looking likely.
I’m struggling to think of another company that has established such a superb growth track record, yet is still reasonably priced.
Hence I’m more than happy to retain my positive view of HVO shares. Kicking myself for having got bored and sold mine in 2023, but never mind. Patience is the difficult bit with investing isn’t it, especially when shares are going nowhere for a while despite good news/figures - you start doubting your own judgement I find. We’re always learning!
HVO shares have been volatile in the past, but the hype of the past has now been transformed into very strong fundamentals, so this recent rise seems far better underpinned by reality - which is also reflected i